0HUZImunon, Inc.
Data unavailable—Mkt Cap: —P/E: —608d ago
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value67.65M $
Revenue (TTM)—
Gross Profit-409.92K $
Net Income (TTM)-14.73M $
Revenue/Share—
Last Price—
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.65
EV/Revenue—
P/S—
P/B2.12
EPS (TTM)-3.97
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-429.72%
ROA-77.99%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.11M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt980.91K $
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity187.29
Current Ratio1.82
Quick Ratio1.44
Book Value/Sh0.4150 USD
Cash/Share1.223 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.066667:1
Split DateMar 1, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float5.28M
Insiders5.73%
Institutions5.68%
Technical
SMA 500.8550 USD
SMA 2001.034 USD
Beta1.98
S&P 52W Chg16.25%
Avg Vol (30d)—
Avg Vol (10d)4.01K
Technical Indicators
RSI (14)48.4
MACD0.0153
MACD Signal0.0141
MACD Hist.+0.0013
BB Upper1.032 USD
BB Middle0.8952 USD
BB Lower0.7584 USD
BB Width30.58%
ATR (14)0.0516 USD
Vol Ratio (20d)0.10x